Comparison of Acid-neutralizing capacity of antacids in Erbil City

Received: 17/2/2020 Accepted: 22/9/2020

Abstract

Background and objective: Antacids are basic substances that can neutralize hydrochloric acid and reduce gastric acidity. They are over the counter drugs used to treat dyspepsia. The most commonly used antacids are sodium bicarbonate, magnesium hydroxide, aluminum hydroxide, and calcium carbonate. This study aimed to evaluate the effectiveness of antacids that are commonly used in Erbil city by finding their acid-neutralizing capacity.

Methods: The method for acid-neutralizing capacity was adapted from pharmacopeia. The samples were prepared by dissolving the antacid in an excess amount of hydrochloric acid, then neutralizing the excess acid with sodium hydroxide solution by doing back titration. The number of milliequivalents that are neutralized by the antacid is the acid-neutralizing capacity of the antacid.

Results: Rennie® chewable tablet showed the highest acid-neutralizing capacity, followed by AntacidAwa and Maalux® plus. The lowest acid-neutralizing capacity was for the suspensions Gaviscon® and Enoxon®.

Conclusion: Acid-neutralizing capacity is an easy and quick method to evaluate the efficacy of antacids. Different combinations of salts and concentrations can affect the acid-neutralizing capacity of the antacid. The higher the neutralizing effect of the antacid, the more effective the antacid is.

Keywords: Acid-neutralizing capacity; Antacid; pH; Dyspepsia; Erbil.

Introduction

Antacids are basic substances that can neutralize hydrochloric acid and reduce gastric acidity. They are over the counter drugs used to treat dyspepsia.1 Most commonly used antacids are sodium bicarbonate, magnesium hydroxide, aluminum hydroxide, and calcium carbonate. All antacids contain bases with a net pH above 7 and buffer. Antacid works based on different mechanisms, including directly neutralizing acidity, increasing the pH, or reversibly reducing or blocking acid secretion by the gastric cell to reduce acidity in the stomach.2 The stomach acid (hydrochloric acid) aids the digestion of food by reducing the pH to less than 3. Once the food is ingested, the production of this acid will increase. Excessive production of acid may lead to heartburn, dyspepsia, acid reflux, and even peptic ulcer. Antacids are the most commonly used substances for treating heartburn and dyspepsia or acid reflux, despite the presence of more effective drugs.3 In general, antacids act by neutralizing stomach acid and increasing gastric pH to 4 and 4.2. This will also reduce the activity of pepsin resulting in symptomatic relief of pain. Antacids also increase the esophageal sphincter lower tone so reduce the reflux of gastric acid or content to the esophagus.2,4 They are weak base substances, commonly hydroxide and carbonate or bicarbonate, which are combined with cations like aluminum, magnesium, sodium, and calcium. Antacids are classified into two main types.

1 Department of Pharmaceutics, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
* Correspondence: jwan.ahmed@hmu.edu.krd
The first type is systemic (absorbable) antacids that are easily absorbed into the systemic circulation and may lead to alkalosis like antacids that contain sodium ion. The second type is non-systemic (non-absorbable) antacids that are not absorbed readily and thus do not make significant systemic effects, such as aluminum containing antacids and magnesium containing antacids. The side effect of the antacid depends on the type of the cation. These over the counter drugs are available in different formulations, either liquid (suspension) or solid (tablet) and are found in pharmacies and markets. The most commonly used antacids consist of a combination of different salts. Some of them may contain alginic acid, which acts as a barrier and protects the gastric mucosa by the formation of a floating raft, thus preventing acid reflux to the esophagus. Simethicone or dimethicone also may be added to antacid formulation to decrease flatulence. The efficacy of antacids is determined by their acid-neutralizing capacity, which is expressed in milliequivalent (mEq). This is defined as the number of mEq of 1N HCL that is brought to pH 3.5 in 15 min. Acid-neutralizing capacity varies within different antacid formulations. The ideal antacid should be effective per unit cost, neutralizing the largest volume of the acid, not producing any systemic side effects like alkalosis, and easily used by the patient. The US FDA requires that an antacid must have a neutralizing capacity of ≥5 mEq per dose. In this research, a comparison of acid-neutralizing capacity was made for five different antacids that are commonly used in Erbil city. This study aimed to evaluate the effectiveness of antacids that are commonly used in Erbil city by finding their acid-neutralizing capacity.

Methods

Materials:
Hydrochloric acid 37% (extra pure, PhEur, BP, NF, Scharlau), sodium hydroxide (extra pure, Ph, BN, Scharlau), distilled water, HANNA instruments pH meter, Sartorius sensitive balance, magnetic stirrer, glassware. All of them were provided by the College of Pharmacy/ Hawler Medical University. Antacids that were tested are Rennei® tablet, Gaviscon® syrup, Maalux® plus, AntacidAwa® tablet (Awamedica), and Enoxon® syrup were obtained from the market.

Methods:
The method for acid-neutralizing capacity was adapted from pharmacopeia. The samples were prepared by dissolving one dose of antacid in 70 ml of distilled water and mixing by a magnetic stirrer for one minute. Then 30 ml of 1N HCL was added with continuous stirring. The stirring was continued for another 15 minutes. Then the sample was titrated with 0.5N NaOH until a stable pH of 3.5 was obtained. The tablets were crushed into fine powder by mortar and pistol before dissolving to simulate disintegration. The acid-neutralizing capacity was calculated by the following equation:

\[ \text{ANC} = (N_{\text{HCl}} \times V_{\text{HCl}}) - (N_{\text{NaOH}} \times V_{\text{NaOH}}) \]

The test was repeated three times for each brand of antacid, and standard deviation was measured. All the work was carried out in the pharmaceutical laboratory of the College of Pharmacy, Hawler Medical University in Erbil city, from September 2019 to January 2020.

Statistical analysis
All experiments were performed in triplicates, and values were expressed as mean ± standard deviation. Statistical significance was assessed using the Kruskal Wallis test with a level of significance of <0.05 followed by Tukey’s Honestly Significance Difference (HSD) method as a Post-hoc analysis.

Results
The antacids used had different ingredients, which are shown in Table 1. Acid-neutralizing capacity for all antacids from different brands was found. The test was done in triplicates for each brand then
the mean and standard deviation was found. The result for each formulation is shown in Table 2 and Figure 1.

**Table 1:** Contents of antacids used in the test.

| Antacids               | Acid-neutralizing capacity | Content                                                                 |
|------------------------|----------------------------|-------------------------------------------------------------------------|
| AntacidAwa® TAB        | 13.5                       | Dried aluminum hydroxide 200mg, magnesium hydroxide 200mg, simethicone 25mg |
| Rennie® tablet         | 18.05                      | Calcium carbonate 680mg, magnesium carbonate 80mg                       |
| Maalux® plus tablet    | 12.5                       | Magnesium hydroxide 200mg, aluminum hydroxide 200mg, dimethicone        |
| Enoxon® oral suspension| 5.65                       | Sodium bicarbonate 267mg, sodium alginate 500mg, calcium carbonate 160mg |
| Gaviscon® oral suspension| 7.25                     | Sodium alginate 500mg, sodium bicarbonate 267mg, calcium carbonate 160mg |

**Table 2:** Results for volume of sodium hydroxide neutralized and acid-neutralizing capacity of the different antacids tested showing the standard deviations.

| Antacids               | Mean volume of NaOH | Mean acid-neutralizing capacity | SD  |
|------------------------|---------------------|---------------------------------|-----|
| Rennie® chewable tablet| 23.9                | 18.05                           | 1.129 |
| AntacidAwa® TAB        | 33                  | 13.5                            | 1.258 |
| Maalux® plus tablet    | 35                  | 12.5                            | 1.607 |
| Enoxon® oral suspension| 47.8                | 5.65                            | 0.546 |
| Gaviscon® oral suspension| 45.5               | 7.25                            | 0.433 |

**Figure 1:** Comparison of acid-neutralizing capacity of the tested antacids.
The statistical analysis of the Kruskal Wallis test showed that $H_c$ is 8.33 while $H$ is 12.9, which means that there is a significant difference between the means of the acid-neutralizing capacity of the different antacids (because $H > H_c$). The Tukey's Honestly Significant Difference (HSD) is 2.720. The post hoc test showed that the acid-neutralizing capacity of AwaTab® and Maalux® plus are similar and those of Enoxon® and Gaviscon® are also similar. All other antacids showed significantly different acid-neutralizing capacity. Table 3 shows the result of the post hoc test.

### Discussion

Antacids are weak bases that can neutralize the acidity of the stomach. The efficacy of antacids is dependent on their acid-neutralizing capacity. All specified antacids have been tested for their acid-neutralizing capacity according to the procedure in USP pharmacopeia.\textsuperscript{12} Rennie chewable tablet was found to have the highest acid-neutralizing capacity being 18.05mEq. AntacidAwa® tablet and Maalux® plus come next being 13.5mEq and 12.5mEq, respectively, showing a non-significant difference with each other but with a significant difference with Rennie® chewable tablet and the other antacids. The suspensions tested showed less acid-neutralizing capacity. The acid-neutralizing capacity for Gaviscon® suspension was 7.25 mEq, and that of Enoxon® suspension was only 5.65 mEq with no significant difference. However, all the antacids showed sufficient acid-neutralizing capacity being greater than 5mEq.\textsuperscript{11} The difference in acid-neutralizing capacity is related to the difference in the bases used and the difference in concentration of the bases. Rennie® chewable tablet contains 680 mg of calcium carbonate and a smaller amount (80mg) of magnesium carbonate. The large amount of calcium carbonate may be responsible for the high acid-neutralizing capacity. Maalux® plus and AntacidAwa® contain the same amounts of the same antacids (aluminum hydroxide and magnesium hydroxide). Thus, they are showing similar acid-neutralizing capacity. It is shown that the calcium and magnesium carbonate salts present in Rennie® provided higher acid-neutralizing capacity compared to the aluminum and magnesium hydroxides present in Maalux® and AntacidAwa® tablets. The results of acid-neutralizing capacity for Rennie®, Maalux® plus, and Gaviscon® suspension were in consistent with the result found for the same brands of antacid from another work done in Iraq by Al-Mudhafar and colleagues (2016).\textsuperscript{13} The two suspension antacids showed the same acid-neutralizing capacity due to that they contain the same amounts of the same bases per each 10 ml of

| Table 3: Post hoc test (Tukey’s Honestly Significance Difference (HSD) is 2.720). |
|-----------------------------------------------|
| Mean acid-neutralizing capacity of Rennie® and AwaTab® differ: 4.266 > 2.720 |
| Mean acid-neutralizing capacity of Rennie® and Maalux® plus differ: 4.766 > 2.720 |
| Mean acid-neutralizing capacity of Rennie® and Enoxon® differ: 12.190 > 2.720 |
| Mean acid-neutralizing capacity of Rennie® and Gaviscon® differ: 10.433 > 2.720 |
| Mean acid-neutralizing capacity of AwaTab® and Maalux® plus are similar: 0.500 < 2.720 |
| Mean acid-neutralizing capacity of AwaTab® and Enoxon® differ: 7.923 > 2.720 |
| Mean acid-neutralizing capacity of AwaTab® and Gaviscon® differ: 6.166 > 2.720 |
| Mean acid-neutralizing capacity of Maalux® plus and Enoxon® differ: 7.423 > 2.720 |
| Mean acid-neutralizing capacity of Maalux® plus and Gaviscon® differ: 5.667 > 2.720 |
| Mean acid-neutralizing capacity of Enoxon® and Gaviscon® are similar: 1.756 < 2.720 |
Conclusion

Acid-neutralizing capacity is an important factor for determining the potency of antacids to provide symptomatic relief from dyspepsia. All antacids showed significant acid-neutralizing capacity. However, Rennie® chewable tablet displayed the highest acid-neutralizing capacity. Thus, it may have a better effect on increasing the pH of the stomach and may show more effect in the treatment of dyspepsia symptoms. The suspensions containing sodium alginate showed lower acid-neutralizing capacity, but the additional effect of the raft may compensate for that.

Competing interests

The authors declare no competing interests.

References

1. Brown M, Sharma P, Mir F, Bennett P. Gastrointestinal system. In: Bans D, Hateley C, Louis J. Clinical Pharmacology, 12th ed. London: Elsevier; 2019. P. 562–94.
2. Abdu K, Abbagan E, Evaluation of neutralizing capacity of different commercial brands of antacid tablets. Chem Search J 2015; 6(2):32–4.
3. Smith G, Arson K. Oxford text book of clinical pharmacology and drug therapy. 3rd ed. New York: Oxford; 2002. P. 276–7.
4. Sathoskar S, Bhandarkar D, Rege N. Pharmacology and pharmacotherapeutics. 21st ed. Mumbai: Popular Prakashan; 2009. P. 612–6.
5. Tripathi D. Essentials of medical pharmacology. 6th ed. New Delhi: Jeyapee; 2008. P. 627–38.
6. Jagadess K, Chidananda K. Study of acid-neutralizing capacity of various antacid formulations. AJPTI 2015; 03(12):113–20.
7. Bhoir S, Bhagwath M. Comparison of seven oxethazine containing antacid available in Indian market. JAPI 2013; 61:400–3.
8. Jakaria M, Zaman R, Parvez M, Islam M, Haque A, Abu Sayeed M, et al. Comparative study among the different formulation of antacid tablets by using acid-base neutralization reaction. Global J Pharmaco 2015; 9(3):278–81.
9. Grinshpan D, Nevar T, Savitskaya T, Boiko A, Kapralov N, Sholomitskaya I. Comparison of acid-neutralizing properties of anti-acid preparations of various compositions. Pharm Chem J 2008; 42:400–4.
10. Jacob S, Shirwaikar A, Anoop S, Khaled R, Imitiaz M, Nair A. Acid neutralization capacity and cost effectiveness of antacids sold in various retail pharmacies in the United Arab Emirates. Hamdan Med J 2016; 9:137–46.
11. Alalor C, Avbunudigba J, Builders F, Okpara L. Evaluation of the acid-neutralizing capacity of Some Commercially Available Brands of Antacid Tablets in Nigeria. East Afr Med J 2019; 2(1):12–6.
12. USP31–NF26, acid-neutralizing capacity, 301. (accessed September 5, 2019, at http://www.uspbpep.com/usps31/v31261/usps31nf26s1_c301.asp).
13. Al-Mudhafar M, Abdulhadi S, Talib B. Evaluation of commercial antacid tablets in Iraq. Der Pharma Chemica 2016; 8(19):283–8.
14. Mandel K, Daggy P, Brodie D, Jacoby H. Alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther 2000; 14:669–90.
15. Prajapati S, Mehta A, Modhia I, Patel C. Formulation and optimisation of raft-forming chewable tablets containing H2 antagonist. Int J Pharm Invest 2012; 2(4):178–82.